58 related articles for article (PubMed ID: 22722648)
1. A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement.
Coltro G; Santi R
Blood; 2023 May; 141(20):2541. PubMed ID: 37200055
[No Abstract] [Full Text] [Related]
2. Osteolytic lesion as initial presentation in FIP1L1-PDGFRA-rearranged myeloid/lymphoid neoplasm with eosinophilia: a case report.
Lv Y; Yao X; Ling Q; Suo S; Wang J; Zhao S; Gao X; Tong H; Jin J; Zhang X; Yu W
Ann Hematol; 2024 Jan; 103(1):357-360. PubMed ID: 37777636
[No Abstract] [Full Text] [Related]
3. False-Negative Testing for FIP1L1::PDGFRA by Fluorescence in situ Hybridization Is a Frequent Cause of Diagnostic Delay.
Pongdee T; Berry A; Wetzler L; Sun X; Thumm L; Yoon P; Kuang FL; Makiya M; Constantine G; Khoury P; Rheinbay E; Lane AA; Maric I; Klion AD
Acta Haematol; 2023; 146(4):316-321. PubMed ID: 37285821
[TBL] [Abstract][Full Text] [Related]
4. T cell phenotype and lack of eosinophilia are not uncommon in extramedullary myeloid/lymphoid neoplasms with ETV6::FLT3 fusion: a case report and review of the literature.
Schoelinck J; Gervasoni J; Guillermin Y; Beillard E; Pissaloux D; Chassagne-Clement C
Virchows Arch; 2023 Nov; ():. PubMed ID: 37985498
[TBL] [Abstract][Full Text] [Related]
5. Myeloid sarcoma and pathological fracture: a case report and review of literature.
Takeyasu S; Morita K; Saito S; Toho M; Oyama T; Obo T; Taoka K; Shimura A; Maki H; Shibata E; Watanabe Y; Suzuki F; Zhang L; Kobayashi H; Hinata M; Kurokawa M
Int J Hematol; 2023 Dec; 118(6):745-750. PubMed ID: 37707761
[TBL] [Abstract][Full Text] [Related]
6. Proof of concept of triple COMBI therapy to prohibit MPN progression to AML.
Hasselbalch HC; Skov V; Kjaer L; Larsen MK
Br J Haematol; 2024 Jan; 204(1):16-18. PubMed ID: 37957927
[TBL] [Abstract][Full Text] [Related]
7. [Bone destruction was the initial symptom in myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of PDGFRα: a case report].
Guo Y; Lyu GQ; Zhang Y; Wang LH; Wu JR; Lu XL; Qin WL; Wu S
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):195. PubMed ID: 38604798
[No Abstract] [Full Text] [Related]
8. A myeloid neoplasm with FIP1L1-PDGFRA presenting as acute myeloid leukemia.
Cadenas FL; Bua BR; Campelo MD; Rieu JB; Bain BJ
Am J Hematol; 2020 Oct; 95(10):1214-1215. PubMed ID: 32311158
[No Abstract] [Full Text] [Related]
9. Marked eosinophilic atypia in a patient with asthma and myeloid/lymphoid neoplasm with FIP1L1::PDGFRA fusion.
Deb PQ; Li L
Br J Haematol; 2024 Apr; ():. PubMed ID: 38685615
[No Abstract] [Full Text] [Related]
10. Eosinophil atypia in a myeloid/lymphoid neoplasm with PDGFRA rearrangement.
Iranzad N; Carlsen ED
Blood; 2024 Jan; 143(1):92. PubMed ID: 38175674
[No Abstract] [Full Text] [Related]
11. A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease.
Chen D; Bachanova V; Ketterling RP; Begna KH; Hanson CA; Viswanatha DS
Am J Surg Pathol; 2013 Jan; 37(1):147-51. PubMed ID: 23232855
[TBL] [Abstract][Full Text] [Related]
12. The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report.
Shatilova A; Girshova L; Zaytsev D; Budaeva I; Mirolyubova Y; Ryzhkova D; Grozov R; Bogdanov K; Nikulina T; Motorin D; Zammoeva D; Efremova S; Ivanov V; Petukhov A; Alekseeva Y; Zaritskey A
BMC Womens Health; 2021 May; 21(1):184. PubMed ID: 33933047
[TBL] [Abstract][Full Text] [Related]
13. Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing.
Mandelker D; Dal Cin P; Jacene HA; Armand P; Stone RM; Lindeman NI
Exp Hematol Oncol; 2015; 4():30. PubMed ID: 26457233
[TBL] [Abstract][Full Text] [Related]
14. Complete response of myeloid sarcoma with FIP1L1-PDGFRA -associated myeloproliferative neoplasms to imatinib mesylate monotherapy.
Tang TC; Chang H; Chuang WY
Acta Haematol; 2012; 128(2):83-7. PubMed ID: 22722648
[TBL] [Abstract][Full Text] [Related]
15. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
Rathe M; Kristensen TK; Møller MB; Carlsen NL
Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
[TBL] [Abstract][Full Text] [Related]
16. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
Metzgeroth G; Walz C; Score J; Siebert R; Schnittger S; Haferlach C; Popp H; Haferlach T; Erben P; Mix J; Müller MC; Beneke H; Müller L; Del Valle F; Aulitzky WE; Wittkowsky G; Schmitz N; Schulte C; Müller-Hermelink K; Hodges E; Whittaker SJ; Diecker F; Döhner H; Schuld P; Hehlmann R; Hochhaus A; Cross NC; Reiter A
Leukemia; 2007 Jun; 21(6):1183-8. PubMed ID: 17377585
[TBL] [Abstract][Full Text] [Related]
17. Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.
Barraco D; Carobolante F; Candoni A; Simeone E; Piccaluga P; Tabanelli V; Fanin R
Eur J Haematol; 2014 Jun; 92(6):541-5. PubMed ID: 24460680
[TBL] [Abstract][Full Text] [Related]
18. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.
Pardanani A; Tefferi A
Leuk Res; 2004 May; 28 Suppl 1():S47-52. PubMed ID: 15036941
[TBL] [Abstract][Full Text] [Related]
19. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.
Savage N; George TI; Gotlib J
Int J Lab Hematol; 2013 Oct; 35(5):491-500. PubMed ID: 23489324
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
